Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05339581
Other study ID # Renji-IIT2022-011
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date May 20, 2022
Est. completion date May 31, 2024

Study information

Verified date April 2022
Source RenJi Hospital
Contact Hao Feng, MD, Ph.D
Phone 008615000901110
Email surgeonfeng@live.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a parallel assigned, open-label, perspective trial studying the safety and efficacy of intensity-modulated radiotherapy (IMRT) combined with PD-1 Blockade and Lenvatinib for Hepatocellular Carcinoma (HCC) with Vp3 Portal Vein Tumor Thrombus (PVTT, Japanese Liver Cancer Study Group classification) before liver transplantation.


Description:

In most criteria (e.g.Milan, UCSF, Up-to-seven), PVTT remains as an absolute contraindication for liver transplant due to the high rate of recurrence and poor prognosis. Neoadjuvant therapy has induced pathological responses in multiple tumor types and might decrease the risk of postoperative recurrence in HCC. The primary endpoint is the necrosis rate of PVTT and the primary tumor. Participants receive PD-1 Blockade (Pembrolizumab,Sintilimab, Camrelizumab,Tislelizumab) 200 mg intravenously on day 1 of a regular treatment cycle and Lenvatinib Mesylate Capsule (Lenvima®) 8 mg orally once daily. Neoadjuvant IMRT will be initiated at the third treatment cycle, and the dose prescription of IMRT is for planning target volume (PTV). The prescription dose to 95%PTV should be ≥50 Gy and ≤60 Gy, and been given in daily dose fractions of 2 Gy, 5 days per week. And the final prescription dose is determined according to dose constraints for organs at risk.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 78
Est. completion date May 31, 2024
Est. primary completion date December 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Patients must have pathologically or cytologically or by radiological criteria proven hepatocellular carcinoma(exceeding Milan criteria); known mixed histology (e.g. hepatocellular carcinoma plus cholangiocarcinoma) or fibrolamellar variant is not allowed. - The maximum diameter of a single tumor =9cm. Or the number of tumors =3 and the maximum diameter of the largest tumors =5cm, and the sum of the maximum diameters of all tumors =9cm. - Vp3 PVTT according to Japanese Vp classification. - Without lymph node metastasis or extrahepatic metastasis. - Baseline AFP=20ng/ mL - Has an eligibility scan (CT of the chest, triphasic CT scan and MRI of the abdomen) <1 week before the treatment. - Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 7 days prior to Cycle 1, Day 1. - Has a Child-Pugh A-B7 liver score (5 to 7 points) within 7 days prior to Cycle 1, Day 1. - Laboratory tests within 7 days prior to Cycle 1, Day 1: - Neutrophils =1.5×109/L - Hemoglobin =8.5g/dL - Platelets =100×109/L, - Creatinine =1.5× upper limit of normal (ULN) and endogenous creatinine clearance =50ml/min (standard Cockcroft Gaul formula) - Total bilirubin =3×ULN, ALT=5×ULN, AST=5×ULN, INR=1.7 - Has controlled hepatitis B (HBV-DNA<105IU/ml) - The estimate time length between enrollment and liver transplantation should be at least 3 months. - No prior systematic therapy such as immunotherapy, targeted therapy and chemotherapy for HCC. - No prior local treatment such as TACE, HAIC, radiofrequency ablation or radiotherapy was received within 2 months before enrollment. - If female, is not pregnant or breastfeeding, and at least one of the following conditions applies: 1) Is not a woman of childbearing potential (WOCBP); or 2) Is a WOCBP and using a contraceptive method that is highly effective or be abstinent from heterosexual intercourse as their preferred and usual lifestyle (a WOCBP must have a negative pregnancy test within 72 hours before the first dose of study treatment). - No obvious insufficiency of other organs. - Patients with a history of hypertension should be well controlled (< 140/90 mmHg) on a regimen of anti-hypertensive therapy. - Patients voluntarily joined the study and signed informed consent with good compliance and follow-up. Exclusion Criteria: - • Known mixed histology (e.g. hepatocellular carcinoma plus cholangiocarcinoma) or fibrolamellar variant. - Surgery within the past 6 months. - Has had esophageal or gastric variceal bleeding within the last 6 months. - Has clinically apparent ascites on physical examination. - Has received systematic therapy such as immunotherapy, targeted therapy and chemotherapy for HCC. - Has received TACE, HAIC, radiofrequency ablation and other local treatments in recent 2 months. - Has received liver radiotherapy. - Has received radiotherapy with grade 4 toxicity. - Significant history of cardiac disease is not allowed: Congestive heart failure > class II New York Heart Association (NYHA) Myocardial infarction within 6 months prior to registration Serious myocardial dysfunction, defined as scintigraphically (multigated acquisition scan [MUGA], myocardial scintigram) determined absolute left ventricular ejection fraction (LVEF) below 45% or an LVEF on echocardiogram (ECHO) below the normal limit at the individual institution. - Has severe hypersensitivity (=Grade 3) to monoclonal antibody. - Has an active autoimmune disease that has required systemic treatment (skin diseases that do not require systemic treatment such as vitiligo, psoriasis; type I diabetes, and autoimmune hypothyroidism due to hormone replacement therapy are allowed). - Patients with other active malignant tumors within 5 years before the first use of the study drug (cured localized tumors such as basal cell carcinoma of skin, squamous cell carcinoma of skin, superficial bladder cancer, carcinoma in situ of prostate, carcinoma in situ of cervix and carcinoma in situ of breast are allowed). - Has an active infection requiring systemic therapy. - Has a known history of human immunodeficiency virus (HIV) infection. - Has known active tuberculosis within 5 years. - Has received a live vaccine within 30 days prior to the first dose of study treatment. - Has received bone-marrow allotransplantation or solid organ transplantation. - Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to Cycle 1, Day 1. - Dysphagia or known drug absorption disorder. - Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study treatment. - Conditions considered unsuitable for inclusion by other researchers.

Study Design


Intervention

Radiation:
intensity-modulated radiotherapy
Neoadjuvant IMRT will be initiated at the third treatment cycle, and the dose prescription of IMRT is for planning target volume (PTV). The prescription dose to 95%PTV should be =50 Gy and =60 Gy, and been given in daily dose fractions of 2 Gy, 5 days per week. And the final prescription dose is determined according to dose constraints for organs at risk.
Combination Product:
Pembrolizumab
Participants receive PD-1 Blockade (Pembrolizumab 200mg,Sintilimab 200mg, Camrelizumab 200mg,Tislelizumab 200mg) 100-200 mg intravenously on day 1 of a regular treatment cycle until >42 days before liver transplantation or unacceptable toxicity develops. Participants receive Lenvatinib Mesylate Capsule (Lenvima®) 8 mg orally once daily until >7 days before liver transplantation.
Drug:
Sintilimab
Sintilimab is a recombinant anti-human PD-1 monoclonal antibody.
Camrelizumab
Camrelizumab is a humanized anti-human PD-1 monoclonal antibody.
Tislelizumab
Tislelizumab is a recombinant anti-human PD-1 monoclonal antibody.
Lenvatinib Mesylate Capsule
Lenvatinib (Lenvima®, Eisai China) is a novel angiogenesis inhibitor which targets vascular endothelial growth factor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptor ß, RET and KIT.

Locations

Country Name City State
China Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University Shanghai

Sponsors (1)

Lead Sponsor Collaborator
RenJi Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary PVTT RR/NR Portal vein tumor thrombus related Response and Necrosis Rate up to 12 months
Secondary Alpha Fetoprotein Response (AFP-R) AFP-R is defined as a >20% decrease in AFP serum level from baseline to the time of liver transplant, if liver transplant is not possible, the final AFP level would be measured as the AFP level at 12 months. up to 12 months
Secondary Progression-free survival (PFS) PFS is defined as the time from the date of treatment initiation to the date of the first observation of progressive disease (PD) by independent radiologic review according to mRECIST criteria or death from any cause. up to 12 months
Secondary Objective Response Rate (ORR) RR is defined as the proportion of patients whose tumor volume has reached a predetermined value and can maintain a minimum time limit, including complete response(CR) and partial response(PR) by independent radiologic review according to mRECIST criteria. up to 12 months
Secondary Time to Progression (TTP) TTP is defined as the duration from the date of patient recruited to the first progress at any site or the date of death from any cause. up to 12 months
Secondary Duration of response (DOR) DOR is defined as the duration from the date that measurement criteria are met for CR or PR to the first progress at any site or the date of death from any cause. up to 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT04209491 - Interest of the Intervention of a Nurse Coordinator in Complex Care Pathway
Completed NCT03963206 - Cabozantinib toLERANCE Study in HepatoCellular Carcinoma (CLERANCE) Phase 4
Completed NCT03268499 - TACE Emulsion Versus Suspension Phase 2
Recruiting NCT05263830 - Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy
Recruiting NCT05044676 - Immune Cells as a New Biomarker of Response in Patients Treated by Immunotherapy for Advanced Hepatocellular Carcinoma
Recruiting NCT05095519 - Hepatocellular Carcinoma Imaging Using PSMA PET/CT Phase 2
Recruiting NCT05497531 - Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers N/A
Completed NCT05068193 - A Clinical Trial to Compare the Pharmacokinetics and Bioequivalence of "BR2008" With "BR2008-1" in Healthy Volunteers Phase 1
Active, not recruiting NCT03781934 - A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations Phase 1/Phase 2
Terminated NCT03655613 - APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC Phase 1/Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT04242199 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors Phase 1
Completed NCT04401800 - Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma Phase 2
Withdrawn NCT05418387 - A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona N/A
Active, not recruiting NCT04039607 - A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma Phase 3
Terminated NCT03970616 - A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma Phase 1/Phase 2
Recruiting NCT04118114 - Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors Phase 2
Recruiting NCT06239155 - A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT03642561 - Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE Phase 2/Phase 3
Completed NCT03222076 - Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer Phase 2